TY - JOUR
T1 - The COVID-19, tuberculosis and HIV/AIDS
T2 - Ménage à Trois
AU - Udoakang, Aniefiok John
AU - Djomkam Zune, Alexandra Lindsey
AU - Tapela, Kesego
AU - Nganyewo, Nora Nghochuzie
AU - Olisaka, Frances Ngozi
AU - Anyigba, Claudia Adzo
AU - Tawiah-Eshun, Sylvia
AU - Owusu, Irene Amoakoh
AU - Paemka, Lily
AU - Awandare, Gordon A.
AU - Quashie, Peter Kojo
N1 - Publisher Copyright:
Copyright © 2023 Udoakang, Djomkam Zune, Tapela, Nganyewo, Olisaka, Anyigba, Tawiah-Eshun, Owusu, Paemka, Awandare and Quashie.
PY - 2023/1/27
Y1 - 2023/1/27
N2 - In December 2019, a novel pneumonic condition, Coronavirus disease 2019 (COVID- 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in China and spread globally. The presentation of COVID-19 is more severe in persons with underlying medical conditions such as Tuberculosis (TB), Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and other pneumonic conditions. All three diseases are of global concern and can significantly affect the lungs with characteristic cytokine storm, immunosuppression, and respiratory failure. Co-infections of SARS-CoV-2 with HIV and Mycobacterium tuberculosis (Mtb) have been reported, which may influence their pathogenesis and disease progression. Pulmonary TB and HIV/AIDS patients could be more susceptible to SARS-CoV-2 infection leading to lethal synergy and disease severity. Therefore, the biological and epidemiological interactions of COVID-19, HIV/AIDS, and TB need to be understood holistically. While data is needed to predict the impact of the COVID-19 pandemic on these existing diseases, it is necessary to review the implications of the evolving COVID-19 management on HIV/AIDS and TB control, including therapy and funding. Also, the impact of long COVID on patients, who may have this co-infection. Thus, this review highlights the implications of COVID-19, HIV/AIDS, and TB co-infection compares disease mechanisms, addresses growing concerns, and suggests a direction for improved diagnosis and general management.
AB - In December 2019, a novel pneumonic condition, Coronavirus disease 2019 (COVID- 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in China and spread globally. The presentation of COVID-19 is more severe in persons with underlying medical conditions such as Tuberculosis (TB), Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and other pneumonic conditions. All three diseases are of global concern and can significantly affect the lungs with characteristic cytokine storm, immunosuppression, and respiratory failure. Co-infections of SARS-CoV-2 with HIV and Mycobacterium tuberculosis (Mtb) have been reported, which may influence their pathogenesis and disease progression. Pulmonary TB and HIV/AIDS patients could be more susceptible to SARS-CoV-2 infection leading to lethal synergy and disease severity. Therefore, the biological and epidemiological interactions of COVID-19, HIV/AIDS, and TB need to be understood holistically. While data is needed to predict the impact of the COVID-19 pandemic on these existing diseases, it is necessary to review the implications of the evolving COVID-19 management on HIV/AIDS and TB control, including therapy and funding. Also, the impact of long COVID on patients, who may have this co-infection. Thus, this review highlights the implications of COVID-19, HIV/AIDS, and TB co-infection compares disease mechanisms, addresses growing concerns, and suggests a direction for improved diagnosis and general management.
KW - COVID-19
KW - HIV/AIDS
KW - co-infection
KW - immunosuppression
KW - pandemic
KW - susceptibility
KW - tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85147770141&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2023.1104828
DO - 10.3389/fimmu.2023.1104828
M3 - Short survey
C2 - 36776887
AN - SCOPUS:85147770141
SN - 1664-3224
VL - 14
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1104828
ER -